• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Philip Morris International Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    6/6/25 4:06:34 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PM alert in real time by email
    false 0001413329 0001413329 2025-06-03 2025-06-03 0001413329 us-gaap:CommonStockMember 2025-06-03 2025-06-03 0001413329 pm:Notes3.375PercentDue2025Member 2025-06-03 2025-06-03 0001413329 pm:Notes2.750PercentDue2026Member 2025-06-03 2025-06-03 0001413329 pm:NotesDue2.875Percent2026Member 2025-06-03 2025-06-03 0001413329 pm:Notes0.125PercentDue2026Member 2025-06-03 2025-06-03 0001413329 pm:Notes3.125PercentDue2027Member 2025-06-03 2025-06-03 0001413329 pm:Notes3.125PercentDue2028Member 2025-06-03 2025-06-03 0001413329 pm:Notes2.875PercentDue2029Member 2025-06-03 2025-06-03 0001413329 pm:Notes3.375PercentDue2029Member 2025-06-03 2025-06-03 0001413329 pm:Notes3.750PercentDue2031Member 2025-06-03 2025-06-03 0001413329 pm:Notes0.800PercentDue2031Member 2025-06-03 2025-06-03 0001413329 pm:Notes3.125PercentDue2033Member 2025-06-03 2025-06-03 0001413329 pm:Notes2.000PercentDue2036Member 2025-06-03 2025-06-03 0001413329 pm:Notes1.875PercentDue2037Member 2025-06-03 2025-06-03 0001413329 pm:Notes6.375PercentDue2038Member 2025-06-03 2025-06-03 0001413329 pm:Notes1.450PercentDue2039Member 2025-06-03 2025-06-03 0001413329 pm:Notes4.375PercentDue2041Member 2025-06-03 2025-06-03 0001413329 pm:Notes4.500PercentDue2042Member 2025-06-03 2025-06-03 0001413329 pm:Notes3.875PercentDue2042Member 2025-06-03 2025-06-03 0001413329 pm:Notes4.125PercentDue2043Member 2025-06-03 2025-06-03 0001413329 pm:Notes4.875PercentDue2043Member 2025-06-03 2025-06-03 0001413329 pm:Notes4.250PercentDue2044Member 2025-06-03 2025-06-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of

    The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 3, 2025

     

     

    Philip Morris International Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Virginia 1-33708 13-3435103

    (State or other jurisdiction

    of incorporation)

    (Commission File Number)

    (I.R.S. Employer

    Identification No.)

     

    677 Washington Blvd, Suite 1100

    Stamford, Connecticut

    06901
    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (203) 905-2410

     

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class  

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, no par value   PM   New York Stock Exchange
    3.375% Notes due 2025   PM25A   New York Stock Exchange
    2.750% Notes due 2026   PM26A   New York Stock Exchange
    2.875% Notes due 2026   PM26   New York Stock Exchange
    0.125% Notes due 2026   PM26B   New York Stock Exchange
    3.125% Notes due 2027   PM27   New York Stock Exchange
    3.125% Notes due 2028   PM28   New York Stock Exchange
    2.875% Notes due 2029   PM29   New York Stock Exchange
    3.375% Notes due 2029   PM29A   New York Stock Exchange
    3.750% Notes due 2031   PM31B   New York Stock Exchange
    0.800% Notes due 2031   PM31   New York Stock Exchange
    3.125% Notes due 2033   PM33   New York Stock Exchange
    2.000% Notes due 2036   PM36   New York Stock Exchange
    1.875% Notes due 2037   PM37A   New York Stock Exchange
    6.375% Notes due 2038   PM38   New York Stock Exchange
    1.450% Notes due 2039   PM39   New York Stock Exchange
    4.375% Notes due 2041   PM41   New York Stock Exchange
    4.500% Notes due 2042   PM42   New York Stock Exchange
    3.875% Notes due 2042   PM42A   New York Stock Exchange
    4.125% Notes due 2043   PM43   New York Stock Exchange
    4.875% Notes due 2043   PM43A   New York Stock Exchange
    4.250% Notes due 2044   PM44   New York Stock Exchange

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 8.01. Other Events.

     

    On June 6, 2025, Philip Morris International Inc. (“PMI”) issued €500,000,000 aggregate principal amount of its 2.750% Notes due 2029 (the “2029 Notes”) and €500,000,000 aggregate principal amount of its 3.250% Notes due 2032 (the “2032 Notes” and, together with the 2029 Notes, the “Notes”). The Notes were issued pursuant to an Indenture dated as of April 25, 2008, by and between PMI and HSBC Bank USA, National Association, as trustee.

     

    In connection with the issuance of the Notes, on June 3, 2025, PMI entered into a Terms Agreement (the “Terms Agreement”) with the underwriters named therein (the “Underwriters”), pursuant to which PMI agreed to issue and sell the Notes to the Underwriters. The provisions of an Underwriting Agreement, dated as of April 25, 2008 (the “Underwriting Agreement”), are incorporated by reference in the Terms Agreement.

     

    PMI has filed with the Securities and Exchange Commission a Prospectus dated February 10, 2023 and a Prospectus Supplement (the “Prospectus Supplement”) dated June 3, 2025 (Registration No. 333-269690) in connection with the public offering of the Notes.

     

    PMI intends to add the net proceeds of the offering to its general funds, which may be used for general corporate purposes, to repay outstanding commercial paper, or to meet its working capital requirements.

     

    The Notes are subject to certain customary covenants, including limitations on PMI’s ability, with significant exceptions, to incur debt secured by liens and engage in sale/leaseback transactions. PMI may redeem the Notes, in whole or in part, at the applicable redemption prices described in the Prospectus Supplement, plus accrued and unpaid interest thereon to, but excluding, the applicable redemption date. PMI may also redeem all, but not part, of the Notes of each series upon the occurrence of specified tax events as described in the Prospectus Supplement.

     

    Interest on the 2029 Notes is payable annually in arrears on June 6 of each year, commencing June 6, 2026, to holders of record on the preceding May 22. Interest on the 2032 Notes is payable annually in arrears on June 6 of each year, commencing June 6, 2026, to holders of record on the preceding May 22.

     

    The 2029 Notes will mature on June 6, 2029 and the 2032 Notes will mature on June 6, 2032.

     

    The Notes will be PMI’s senior unsecured obligations and will rank equally in right of payment with all of its existing and future senior unsecured indebtedness.

     

    For a complete description of the terms and conditions of the Underwriting Agreement, the Terms Agreement and the Notes, please refer to such agreements and the form of Notes, each of which is incorporated herein by reference and is an exhibit to this report as Exhibits 1.1, 1.2, 4.1 and 4.2, respectively.

     

    Certain of the Underwriters and their respective affiliates have, from time to time, performed, and may in the future perform, various financial advisory, commercial and investment banking services for PMI, for which they received or will receive customary fees and expenses. Certain of the Underwriters and their respective affiliates are lenders under PMI’s credit facilities. PMI and some of its subsidiaries may enter into foreign exchange and other derivative arrangements with certain of the Underwriters or their respective affiliates. In addition, certain of the Underwriters or their respective affiliates act as dealers in connection with PMI’s commercial paper programs.

     

     

     

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit 
    Number
    Description
       
    1.1 Underwriting Agreement, dated as of April 25, 2008 (incorporated by reference to Exhibit 1.1 of PMI’s Registration Statement on Form S-3 (No. 333-150449))
       
    1.2 Terms Agreement, dated June 3, 2025, among PMI and the underwriters named therein
       
    4.1 Form of 2.750% Notes due 2029
       
    4.2 Form of 3.250% Notes due 2032
       
    5.1 Opinion of Hunton Andrews Kurth LLP
       
    104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document and contained in Exhibit 101)

     

     

     

     

    SIGNATUREs

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      PHILIP MORRIS INTERNATIONAL INC.
       
      By: /s/ DARLENE QUASHIE HENRY
      Name: Darlene Quashie Henry
      Title: Vice President, Associate General Counsel and Corporate Secretary

     

    DATE: June 6, 2025

     

     

    Get the next $PM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PM

    DatePrice TargetRatingAnalyst
    5/22/2025$195.00Buy
    Needham
    4/25/2025$170.00Sell → Neutral
    UBS
    3/14/2025Hold → Buy
    Argus
    1/16/2025$140.00Overweight
    Morgan Stanley
    3/5/2024Buy → Hold
    Argus
    2/13/2024Sell → Hold
    Societe Generale
    1/23/2024$105.00 → $86.50Buy → Sell
    UBS
    11/16/2023$95.00Neutral
    Redburn Atlantic
    More analyst ratings

    $PM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham initiated coverage on Philip Morris International with a new price target

      Needham initiated coverage of Philip Morris International with a rating of Buy and set a new price target of $195.00

      5/22/25 8:27:06 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International upgraded by UBS with a new price target

      UBS upgraded Philip Morris International from Sell to Neutral and set a new price target of $170.00

      4/25/25 8:25:28 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International upgraded by Argus

      Argus upgraded Philip Morris International from Hold to Buy

      3/14/25 7:44:58 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    SEC Filings

    See more
    • SEC Form 11-K filed by Philip Morris International Inc

      11-K - Philip Morris International Inc. (0001413329) (Filer)

      6/27/25 3:14:58 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Philip Morris International Inc. (0001413329) (Filer)

      6/24/25 8:10:16 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Philip Morris International Inc. (0001413329) (Filer)

      6/13/25 6:06:09 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Philip Morris International Declares Regular Quarterly Dividend of $1.35 Per Share

      Regulatory News: The Board of Directors of Philip Morris International Inc. (PMI) (NYSE:PM) today declared a regular quarterly dividend of $1.35 per common share, payable on July 15, 2025, to shareholders of record as of June 27, 2025. The ex-dividend date is June 27, 2025. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primar

      6/13/25 5:45:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Illicit Cigarettes in European Union at Highest Level Since 2015, KPMG Study Shows

      Smokers in the European Union (EU) consumed 38.9 billion illicit cigarettes in 2024, a 10.8% increase versus 2023, with serious repercussions for tax revenues, crime rates, and public health. France, the largest illicit market in Europe, reached 18.7 billion illicit cigarettes consumed last year, 37.6% of total consumption. Adding 10.2 ppt year-on-year, the Netherlands saw the largest increase in illicit cigarettes share, which doubled to 17.9% of total consumption. Countries such as Bulgaria, Greece, Italy and Portugal—and Ukraine, outside the EU—have shown sizeable decreases in illicit consumption in 2024. Greece and Ukraine, in particular, saw as much as 30% declines vs. 2023.

      6/11/25 6:00:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Participates in dbAccess Global Consumer Conference

      Reaffirms 2025 Full-Year Forecast for Reported Diluted EPS of $7.01 to $7.14 and Adjusted Diluted EPS of $7.36 to $7.49, Representing Growth of 12% to 14%, 10.5% to 12.5% Excluding Currency Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE:PM) Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2025 dbAccess Global Consumer Conference in Paris. The event will be webcast live in listen-only mode, beginning at approximately 11:15 a.m. CEST (5:15 a.m. EST), at www.pmi.com/2025dbaccess and on the PMI Investor Relations Mobile Application (www.pmi.com/irapp). An archived copy of the webcast will be available for approximately one year. 2025 Full-Ye

      6/3/25 1:30:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Trumpaitis Mindaugas claimed ownership of 73,002 shares (SEC Form 3)

      3 - Philip Morris International Inc. (0001413329) (Issuer)

      6/9/25 3:34:30 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Temperley Dessislava was granted 1,002 shares, increasing direct ownership by 15% to 7,756 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      5/9/25 4:54:43 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Bough Bonin was granted 1,002 shares, increasing direct ownership by 11% to 9,834 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      5/9/25 4:54:34 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      2/9/24 6:21:26 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      2/9/24 6:05:54 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      1/29/24 3:26:29 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Leadership Updates

    Live Leadership Updates

    See more
    • Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

      Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

      9/17/24 9:11:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Names New External Affairs Leader

      Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what

      3/26/24 5:48:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International's U.S. Business Champions Female Economic Growth in Connecticut with Record-Setting $5 Million Investment Through New Partnership with Women's Business Development Council

      In honor of Women's History Month and in advance of International Women's Day, investment and partnership support female economic empowerment and equality through entrepreneurship Today, Philip Morris International (PMI) (NYSE:PM) announces the launch of an extended partnership via its U.S. business to support female empowerment with a record-setting $5 million investment in the Women's Business Development Council (WBDC), a 501(c)(3) charitable organization dedicated to providing tools and resources to help women entrepreneurs thrive in business throughout Connecticut. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202403048002

      3/4/24 6:48:00 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Financials

    Live finance-specific insights

    See more
    • Philip Morris International Declares Regular Quarterly Dividend of $1.35 Per Share

      Regulatory News: The Board of Directors of Philip Morris International Inc. (PMI) (NYSE:PM) today declared a regular quarterly dividend of $1.35 per common share, payable on July 15, 2025, to shareholders of record as of June 27, 2025. The ex-dividend date is June 27, 2025. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primar

      6/13/25 5:45:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Participates in dbAccess Global Consumer Conference

      Reaffirms 2025 Full-Year Forecast for Reported Diluted EPS of $7.01 to $7.14 and Adjusted Diluted EPS of $7.36 to $7.49, Representing Growth of 12% to 14%, 10.5% to 12.5% Excluding Currency Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE:PM) Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2025 dbAccess Global Consumer Conference in Paris. The event will be webcast live in listen-only mode, beginning at approximately 11:15 a.m. CEST (5:15 a.m. EST), at www.pmi.com/2025dbaccess and on the PMI Investor Relations Mobile Application (www.pmi.com/irapp). An archived copy of the webcast will be available for approximately one year. 2025 Full-Ye

      6/3/25 1:30:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Reports First-Quarter 2025 Results and Raises 2025 Full-Year Adjusted Diluted EPS Forecast for Currency Only

      Reported Diluted EPS Grew 24.6% to $1.72 Adjusted Diluted EPS Grew 12.7% to $1.69; and by 17.3% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 first-quarter results.1 "We achieved exceptionally strong performance in the first quarter, with continued volume growth supporting an excellent top-line performance and very strong margin expansion," said Jacek Olczak, Chief Executive Officer. "Our smoke-free business goes from strength to strength, delivering organic growth of over 20% in net revenues and over 33% in gross profit." "We remain confident in our ability to deliver superior results, despite an uncertain and volatile glob

      4/23/25 6:59:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care